Asthma is a common and potentially life-threatening chronic inflammatory airway disease. Despite many therapeutic advances, it remains underdiagnosed and undertreated. The mainstay of therapy is maintenance controller therapy such as inhaled corticosteroids, together with separate short-acting β2-agonists for acute symptom relief, but treatment adherence is a major challenge. The heterogeneity of asthma makes it difficult to identify specific therapeutic targets. For patients with specific subtypes of severe asthma, such as eosinophilic asthma, targeted therapies including omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab, can reduce exacerbation rates and improve disease control. As experience with biological therapies increases, they are expected to play a more prominent role in treatment strategies, and novel therapeutic targets such as semaphorins and RhoA/Rho‐kinase, are being investigated.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
In the US, 26.8 million people have asthma, including 4.5 million children. Asthma accounts for millions of emergency department visits, tens of billions in healthcare costs and thousands of missed school days each year. The American Lung Association’s Promoting Asthma-Friendly Environments through Partnerships and Collaborations brings together a network of programs to help children better manage their asthma.
Effective asthma management requires more than medication alone. Education, self-management support, and early intervention are essential to helping patients achieve better symptom control and improved quality of life. To address these needs, the American Lung Association has developed a range of evidence-based asthma programs for both adults and children, designed to build practical skills, improve adherence, and support long-term disease management across home, school, and community settings.
Asthma and COPD are common airway diseases with distinct underlying mechanisms, yet in everyday practice many patients present with features of both. Differentiating between asthma-predominant and COPD-predominant disease is an important clinical challenge, with significant implications for diagnosis, treatment selection, and long-term outcomes. In this Q&A, Prof. Felix Herth discusses how clinicians can approach patients with overlapping features of asthma and COPD, including the role of clinical history, lung function testing, biomarkers, imaging, treatment selection, and the importance of reassessing response to therapy over time.
Obesity is increasingly recognized as an important contributor to asthma severity, with both mechanical and inflammatory mechanisms linked to worse symptoms and more frequent exacerbations. Recently, GLP-1 receptor agonists have emerged as important therapies for obesity management, with growing interest in their potential benefits beyond weight reduction. In this Q&A, touchRESPIRATORY spoke with Dr Ruchi Patel about the impact of obesity on asthma, the emerging evidence linking GLP-1 receptor agonists with reduced exacerbations, and the key findings and clinical implications of her recent research.
In this year-end review, we are pleased to share personal highlights from members of the touchRESPIRATORY Editorial Board and this year's Future Leaders cohort, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
The 2025 American College of Allergy, Asthma & Immunology (ACAAI; November 6−10, Orlando, Florida, USA) annual meeting showcased emerging therapies and real-world insights across eosinophilic disorders, atopic disease, chronic respiratory conditions, and allergic rhinitis. From late-breaking clinical trial results to observational data, the conference highlighted advances in convenient, effective, and targeted therapies for patients, as well as strategies to optimize long-term disease management.
Watch short presentations and panel discussion with leading respiratory experts, who'll discuss clinical remission as an ambitious but achievable treatment goal for patients with asthma, and how to implement and achieve this goal in routine clinical practice.
The ERS Congress 2025 in Amsterdam showcased the latest advances in respiratory medicine, featuring cutting-edge research, interactive workshops, and sessions across 14 specialist assemblies. Highlights included live endoscopy demonstrations, updates on lung cancer projects, and innovative programmes for early career professionals. This year’s congress underscored global collaboration and innovation in respiratory health. touchRESPIRATORY were delighted to speak with leading experts at ERS 2025, sharing insights on some of the congress’s key presentations and breakthroughs in respiratory medicine.
Extreme weather and air pollution can pose serious risks for people living with asthma and COPD. In this interview, Dr Tugce Karamustafalioglu discusses her award-winning study on how heatwaves and poor air quality worsen symptoms, reduce quality of life, and increase exacerbations, while offering practical advice for protecting vulnerable patients.
Severe asthma has a profound impact on patients’ quality of life, yet many aspects remain underappreciated. This Q&A Dr Joseph Lanario explores findings from SHARP, a pan-European research consortium, including variability in patient response to biologic treatments and factors driving fatigue. Learn how these insights from patient-reported outcomes are shaping research, guiding clinical practice, and informing strategies to improve care for people living with severe asthma.
The phase 2 TIDE-Asthma (NCT05421598) study is investigating amlitelimab, an OX40L inhibitor, as an add-on therapy for moderate-to-severe asthma. In this Q&A, Dr Praveen Akuthota discusses the drug’s mechanism of action, study aims and design, key clinical endpoints, the findings shared at the ERS International Congress 2025, and the potential impact on future asthma treatment.
A Phase 2, multicentre trial is evaluating a novel inhaled formulation of itraconazole in patients with ABPA-complicating asthma. This study aims to assess the safety, optimal dosing, and potential clinical benefits of delivering antifungal therapy directly to the lungs, addressing a key unmet need in this challenging condition.
We are deeply saddened to share the passing of Dr Ronald A Strauss, an esteemed member of the Editorial Board of touchREVIEWS in Respiratory & Pulmonary Diseases, who died on 12 January 2025 at the age of 80 in Cleveland Heights, OH, USA. ...
It is my great pleasure to introduce touchREVIEWS in Respiratory & Pulmonary Diseases, Volume 10, Issue 1, 2025. This issue brings together a collection of timely and thought-provoking articles addressing key challenges and emerging innovations across the spectrum of respiratory and pulmonary care. ...
EUFOREA has expanded its Patient Portal to include asthma, offering reliable, expert-backed resources for people living with chronic respiratory diseases (CRDs) such as asthma, chronic rhinosinusitis (CRS), and COPD. In this Q&A, Dr. Sophie Scheire, EUFOREA’s Patient Education Manager, discusses how the portal helps bridge the knowledge gap, combat misinformation, and empower patients to take charge of their health, while also supporting healthcare professionals in providing better care.
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright! This year, we are celebrating our inaugural touchRESPIRATORY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform respiratory and pulmonary medicine in the years to come.
Future Leader Dr Joseph Lanario, Research Fellow at the University of Birmingham, is advancing patient-reported outcome tools to more accurately capture the lived impact of severe asthma. Co-author of the Severe Asthma Questionnaire, now embedded in international core measures, he leads the Inclusive PRO study to overcome barriers such as digital exclusion and disability, ensuring respiratory research represents all patient experiences.
The GINA 2025 strategy report introduces a more personalised, age-specific, and proactive approach to asthma care. Key updates include the shift away from SABA monotherapy, expanded use of biomarkers for treatment guidance, and increased emphasis on environmental factors like climate change. The guidelines highlight shared decision-making, routine monitoring, and tailored treatment plans, aiming to reduce exacerbations and improve outcomes across all age groups.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.